CME HRPZ II 02 APRIL 2026 :The Incretin Revolution: Navigating Benefits, Risks, and New Agents

The discovery of incretin-based therapies such as Ozempic and Mounjaro have been momentous in the treatment of diabetes and obesity. This session aims to provide an overview of current available incretin-based therapies, adverse effects associated with them and considerations in utilising these revolutionary agents. Learning Points: 🔵Describe the incretin effect and how modern incretin agonists leverage this pathway. 🔵Illustrate the role of incretin based therapies in managing diabetes and obesity & their effects beyond glycemic control. Penceramah: Nor Akila binti Mahmood Pegawai Farmasi UF14 Jabatan Farmasi